Nextgen Healthcare — Proxy Contest (September 2021)
70 slides from Nextgen Healthcare's proxy contest presentation, Sep 23, 2021
Slide 1: Resetting the Balance of Power in NextGen Healthcare's Boardroom
RESETTING THE BALANCE OF POWER IN NEXTGEN HEALTHCARE’S BOARDROOM PREPARED BY THE RAZIN GROUP SEPTEMBER 2021
Slide 2: Disclaimer
DISCLAIMER The materials contained herein (the “Materials”) represent the opinions of Sheldon Razin and the other participants named in his proxy solicitation (collectively, the “Razin Group”) and are based on publicly available information with respect to NextGen Healthcare, Inc. (the “Company”). T
Slide 3: Contents
CONTENTS I Executive Summary………………………………………………………………………………......Pg. 4 II A Closer Look: The Case for Change………………………………………………Pg. 29 III A Closer Look: The Anti-Shareholder Reincorporation…....Pg. 47 IV Our Solution: The Razin Group Slate……………………………………………...Pg. 53 V Our Vision For Improving NextGen H
Slide 4: Executive Summary
EXECUTIVE SUMMARY
Slide 5: What This Election Contest Is About
WHAT THIS ELECTION CONTEST IS ABOUT This contest is about resetting the balance of power in NextGen Healthcare’s dysfunctional and insular boardroom in order to ensure that shareholders’ best interests are prioritized following six years of anemic revenue growth, deteriorating earnings, dismal capit
Slide 6: What This Election Contest Is Not About
WHAT THIS ELECTION CONTEST IS NOT ABOUT This contest is not about attaining boardroom control, reinstating a dividend or any short-term motivations – to the contrary, Messrs. Razin and Rosenzweig want to establish an enduring culture of accountability and a foundation for value creation that will co
Slide 7: Introduction to the Razin Group
INTRODUCTION TO THE RAZIN GROUP The Razin Group, led by two current NextGen Healthcare Board members, has nominated a minority slate of four director candidates to reset the balance of power in the boardroom at the Company’s 2021 Annual Meeting Sheldon Razin Lance E. Rosenzweig • Mr. Razin is the fo
Slide 8: The Razin Group Nominees
THE RAZIN GROUP NOMINEES Our nominees have the right experience to help turn around NextGen Healthcare for all shareholders Kenneth H. Fearn Sheldon Razin Lance E. Rosenzweig Ruby Sharma 9 25+ years of experience 9 Founder and current director 9 Current director of NextGen 9 Former Principal at Erns
Slide 9: Introduction to NextGen Healthcare
INTRODUCTION TO NEXTGEN HEALTHCARE NextGen Healthcare is a stagnant healthcare technology business that has fallen behind peers and produced no meaningful value for shareholders during the six-year chairmanship of Jeffrey Margolis Business Summary Financial Snapshot* • NextGen Healthcare is a nation
Slide 10: NextGen Healthcare Has Underperformed for Far Too Long
NEXTGEN HEALTHCARE HAS UNDERPERFORMED FOR FAR TOO LONG The Company has underperformed over every relevant time horizon during the period in which Mr. Margolis and the directors we are seeking to replace have controlled the Board 166% 161% 150% 150.00% 131% 100.00% 93% 84% 63% 48% 50.00% 37% 35% 31%
Slide 11: NextGen Healthcare's Shares Now Trade at a Punishing Discount
NEXTGEN HEALTHCARE’S SHARES NOW TRADE AT A PUNISHING DISCOUNT The Company’s shares currently trade at a multiple of less than 2x annual revenue, while a majority of proxy peers are trading at multiples of more than 4x annual revenue 18 16 14 12 Revenue Multiple (x) 10 8 6 4 2 0 Source: Company filin
Slide 12: Mr. Margolis and the Board's Leaders Bear Accountability
MR. MARGOLIS AND THE BOARD’S LEADERS BEAR ACCOUNTABILITY Mr. Margolis and his hand-picked committee chairs have presided over years of stagnation, while continuously concentrating their power, reaping outsized compensation and stifling boardroom debate • Mr. Margolis and his allies have effectively
Slide 13: The Margolis Board Has Fostered Dismal Corporate Governance
THE MARGOLIS BOARD HAS FOSTERED DISMAL CORPORATE GOVERNANCE Mr. Margolis and his committee chairs have consistently undermined the tenets of sound governance, as evidenced by the following issues: CONCERNING BOARDROOM LACK OF SUCCESSION HISTORY OF OPAQUE INTERLOCKS PLANNING DISCLOSURES POOR EXECUTIV
Slide 14: The Margolis Board Has Pursued Brazen Entrenchment Tactics
THE MARGOLIS BOARD HAS PURSUED BRAZEN ENTRENCHMENT TACTICS Mr. Margolis and his allies, who collectively own a de minimis number of shares, have recently proposed an unprecedented Delaware reincorporation in the face of an election contest to further entrench themselves and limit their accountabilit
Slide 15: The Margolis Board Has Embraced a Failed Acquisitions Strategy
THE MARGOLIS BOARD HAS EMBRACED A FAILED ACQUISITIONS STRATEGY Mr. Margolis and his allies need to be held accountable for a “strategy” that has not produced value for shareholders Deals Between 2016-2019 X More than $200 million spent between 2016 and 2019 has done little more than conceal the Comp
Slide 16: The Margolis Board Has Made Empty Promises for Years
THE MARGOLIS BOARD HAS MADE EMPTY PROMISES FOR YEARS Under Mr. Margolis’ leadership, NextGen Healthcare has repeatedly claimed to be on the precipice of major organic growth for 19 consecutive quarters “ This continued progress makes us confident in our “ We remain confident in our growth strategy,
Slide 17: Marginal Increase in Revenue Compared to Peers
THE MARGOLIS BOARD HAS SEEN A MARGINAL INCREASE IN REVENUE COMPARED TO PEERS Despite 19 consecutive quarters of claims that the Company is on the precipice of major growth, NextGen Healthcare’s revenue only grew 13% under Mr. Margolis – compared to an average 28% increase from peers – while client a
Slide 18: The Razin Chairmanship Ended with a 100% Increase in Annual Revenue
THE RAZIN CHAIRMANSHIP ENDED WITH A 100% INCREASE IN ANNUAL REVENUE During Mr. Razin’s last seven years as Chairman, the Company’s annual revenue rose ~100% – compared to a mere 13% increase under Mr. Margolis NextGen Healthcare's Annual Revenue Increased 100% During Mr. Razin's Last Seven Years as
Slide 19: The Margolis Board Has Endorsed Non-Accretive Spending
THE MARGOLIS BOARD HAS ENDORSED NON-ACCRETIVE SPENDING Despite steady increases in annual spending, the Company has not seen organic growth or share price appreciation – raising questions about what the Board is investing in SG&A has Risen By 15% Since Mr. Margolis Became Chairman in FY2016 $200,000
Slide 20: Egregious Amount of Revenue Spent on SG&A Expenses
THE MARGOLIS BOARD HAS SPENT AN EGREGIOUS AMOUNT OF REVENUE ON SG&A EXPENSES On average, the Margolis Board has spent 32% of NextGen Healthcare’s annual revenue on unnecessary SG&A expenses – while peers have spent roughly 19% of their annual revenue on SG&A costs On Average, NextGen Healthcare Has
Slide 21: The Margolis Board Has Rewarded Executives for Meager Results
THE MARGOLIS BOARD HAS REWARDED EXECUTIVES FOR MEAGER RESULTS During Mr. Barbarosh’s tenure as Chair of the Compensation Committee, the Board abandoned performance-based vesting in favor of straight share grants and ineffective grants measured against the Company’s budget Total Executive Compensatio
Slide 22: Unjustifiably High Director Fees
THE MARGOLIS BOARD SUPPORTED UNJUSTIFIABLY HIGH DIRECTOR FEES We believe Mr. Margolis and his allies’ interests are misaligned with shareholders, as evidenced by the fact that director compensation is up ~50% during a period in which shareholders have seen no material value creation Total Board Comp
Slide 23: The Margolis Board Dropped the Ball on Succession Planning
THE MARGOLIS BOARD DROPPED THE BALL ON SUCCESSION PLANNING NextGen Healthcare was forced to operate without an interim or permanent chief executive for three months due to the Margolis Board’s failure to develop robust succession plans • NextGen Healthcare’s stock price fell nearly 5% following the
Slide 24: The Margolis Board Ran a Questionable CEO Search Process
THE MARGOLIS BOARD RAN A QUESTIONABLE CEO SEARCH PROCESS We find it alarming that the Board not only hired a new leader during a contested election, but also deliberately kept two directors – Messrs. Razin and Rosenzweig – in the dark when making the hiring decision • We have reason to believe that
Slide 25: Distortions and Misrepresentations About the Razin Group
THE MARGOLIS BOARD HAS RESORTED TO PEDDLING DISTORTIONS AND MISREPRESENTATIONS ABOUT THE RAZIN GROUP THE MARGOLIS BOARD’S CLAIMS THE REALITY 9 The Margolis-led Board ran a failed process to sell the Company, curiously X Mr. Razin hid from the Board side conversations he was purportedly having exclud
Slide 26: Our Solution: The Razin Group's Minority Slate
OUR SOLUTION: THE RAZIN GROUP’S MINORITY SLATE Our nominees collectively possess the experience, perspectives and knowledge that have been marginalized in the boardroom over the past six years Kenneth H. Fearn Sheldon Razin Lance E. Rosenzweig Ruby Sharma • 25+ years of experience advising • Founder
Slide 27: Our Solution: A Slate with a Constructive Vision
OUR SOLUTION: A SLATE WITH A CONSTRUCTIVE VISION Although the Razin Slate would only be a minority of the Board, our nominees would attempt to work constructively with the other Board members to implement their actionable ideas for establishing a culture of innovation, transparency and value creatio
Slide 28: The Takeaway: Now Is the Time to Reset the Balance of Power
THE TAKEAWAY: NOW IS THE TIME TO RESET THE BALANCE OF POWER IN NEXTGEN HEALTHCARE’S BOARDROOM As a new Chief Executive Officer takes the helm, shareholders have a unique opportunity to establish a new corporate culture by ridding the Board of imperial directors who have already failed to empower, in
Slide 29: A Closer Look: The Case for Boardroom Change
A CLOSER LOOK: THE CASE FOR BOARDROOM CHANGE
Slide 30: Sustained Financial Underperformance
SUSTAINED FINANCIAL UNDERPERFORMANCE Relevant small cap indices outperformed NextGen Healthcare by over 50x during Chairman Margolis’ tenure NextGen Healthcare's Total Shareholder Returns Lag Indices Over Every Time Horizon 166% 161% 150% 150.00% 131% 100.00% 93% 84% 63% 48% 50.00% 37% 35% 31% 32% 3
Slide 31: Sustained Financial Underperformance (Cont.)
SUSTAINED FINANCIAL UNDERPERFORMANCE (CONT.) NextGen Healthcare’s performance under Mr. Margolis does not track with the tremendous growth realized by many of its peers during the same time period NextGen Healthcare’s Total Shareholder Returns Under Mr. Margolis Are A Paltry 2.67% 450.00% 400.00% 35
Slide 32: A Consequence of Underperformance: A Steep Trading Discount
A CONSEQUENCE OF UNDERPERFORMANCE: A STEEP TRADING DISCOUNT The Company’s shares trade at a multiple of less than 2x annual revenue, while certain high-performing peers are trading at multiples of more than 4x annual revenue NextGen Healthcare Trades Lower Than Vast Majority of Peers 18 16 14 Revenu
Slide 33: Numerous Boardroom Issues
NUMEROUS BOARDROOM ISSUES Mr. Margolis and his allies have created a toxic boardroom environment to the detriment of shareholders IMPERIAL BOARDROOM CULTURE FOSTERED UNDER MR. MARGOLIS TROUBLING RISING DIRECTOR INTERCONNECTIVITY COMPENSATION ILLOGICAL EXECUTIVE DISMAL CAPITAL COMPENSATION MODEL ALLO
Slide 34: Boardroom Issue #1: Imperial Culture Under Mr. Margolis
BOARDROOM ISSUE #1: IMPERIAL CULTURE UNDER MR. MARGOLIS Mr. Margolis and his allies have effectively assumed control of the Company, which has thwarted the Razin Group’s ability to help deliver strong value to shareholders • For years, Mr. Margolis and his allies, Craig Barbarosh, George Bristol and
Slide 35: Boardroom Issue #2: Troubling Interconnectivity
BOARDROOM ISSUE #2: TROUBLING INTERCONNECTIVITY Board leadership has a deeply rooted history of interrelationships and conflicts of interest James C. Malone Craig Barbarosh • Imperial Chairman Margolis has wasted tens of millions of dollars in shareholder capital on unnecessary and ineffective consu
Slide 36: Boardroom Issue #2: Troubling Interconnectivity (Cont.)
BOARDROOM ISSUE #2: TROUBLING INTERCONNECTIVITY (CONT.) Interrelationships are impairing the Board’s ability to conduct an objective and robust search process for executives and new directors The recent director search resulted in the nomination of two new Board members, both of whom have ties to Ma
Slide 37: Boardroom Issue #3: Poor Succession Planning
BOARDROOM ISSUE #3: POOR SUCCESSION PLANNING In the face of repeated suggestions from the Razin Group, Board leadership failed to establish a succession plan despite years of underperformance under the former CEO Mr. Margolis and his allies ignored suggestions about the need for a succession plan an
Slide 38: Boardroom Issue #3: Poor Succession Planning (Cont.)
BOARDROOM ISSUE #3: POOR SUCCESSION PLANNING (CONT.) The Margolis Board rushed into hiring a new CEO • The Razin Group implored the Margolis-led Board to refrain from hiring a new CEO until after the election of directors at the Annual Meeting • The Margolis Board’s decision to hire a new CEO during
Slide 39: Boardroom Issue #4: An Illogical Executive Compensation Model
BOARDROOM ISSUE #4: AN ILLOGICAL EXECUTIVE COMPENSATION MODEL The entrenched directors are de minimis owners of NextGen Healthcare, who perpetuate their misalignment with shareholders by upholding a compensation model not tied to performance • In recent years, the Company’s executive compensation pl
Slide 40: Boardroom Issue #4: Executive Compensation Model (Cont.)
BOARDROOM ISSUE #4: AN ILLOGICAL EXECUTIVE COMPENSATION MODEL (CONT.) NextGen Healthcare’s former CEO was rewarded compensation at competitive levels that met or exceeded the market, despite shareholder value remaining essentially flat Historical NextGen Healthcare CEO Total Direct Compensation (“TD
Slide 41: Boardroom Issue #5: Dismal Capital Allocation
BOARDROOM ISSUE #5: DISMAL CAPITAL ALLOCATION The Margolis-led Board has overseen a wasteful capital allocation policy that includes egregious overhead costs Prior to Mr. Margolis becoming Chairman in 2015, the Company NextGen Healthcare Operating Expenses vs. Liquidity ($ in had strong cash flow, h
Slide 42: Boardroom Issue #5: Dismal Capital Allocation (Cont.)
BOARDROOM ISSUE #5: DISMAL CAPITAL ALLOCATION (CONT.) NextGen Healthcare’s $165 million acquisition of HealthFusion was its first and most egregious purchase under Mr. Margolis x In 2016, NextGen Healthcare acquired HealthFusion, makers of the MediTouch platform, for $165 million plus potential addi
Slide 43: Boardroom Issue #5: Dismal Capital Allocation (Cont.)
BOARDROOM ISSUE #5: DISMAL CAPITAL ALLOCATION (CONT.) The HealthFusion acquisition lacked synergies and temporarily piled debt on the Company’s balance sheet, making it a complete failure x NextGen Healthcare's business model focused on multi-site, enterprise offices while HealthFusion's MediTouch w
Slide 44: Boardroom Issue #6: Rising Director Compensation
BOARDROOM ISSUE #6: RISING DIRECTOR COMPENSATION Mr. Margolis and his allies have continued to increase Board compensation – paying themselves between 80-125% higher than the market – despite presiding over a period of lackluster performance Total Direct Compensation NACD2 Median TDC NXGN TDC Varian
Slide 45: Boardroom Issue #7: Slow to Embrace Diversity, Equity and Inclusion
BOARDROOM ISSUE #7: SLOW TO EMBRACE DIVERSITY, EQUITY AND INCLUSION NextGen Healthcare’s lack of gender and racial diversity in both the boardroom and C-suite is apparent NXGN Board of Directors NXGN C-Suite The Company has been slow to adopt boardroom diversity and recruiting the next generation of
Slide 46: Recap: The Board Is Threatening Shareholders' Long-Term Interests
RECAP: THE BOARD IS THREATENING SHAREHOLDERS’ LONG-TERM INTERESTS If Mr. Margolis and his allies truly have shareholders’ best interests in mind, we question why they would: 1. Consistently dismiss divergent viewpoints and focus instead on tightening their power grip in the boardroom? 2. Attempt to
Slide 47: A Closer Look: The Anti-Shareholder Reincorporation
A CLOSER LOOK: THE ANTI-SHAREHOLDER REINCORPORATION
Slide 48: No Good Reason for the Reincorporation Proposal at the Annual Meeting
THERE IS NO GOOD REASON FOR THE REINCORPORATION PROPOSAL TO BE CONSIDERED AT THE ANNUAL MEETING The Margolis Board has gone to great lengths and expense to jam through a shareholder-unfriendly Delaware Reincorporation solely to eliminate cumulative voting, despite the Razin Group having committed no
Slide 49: Realities of the Proposed Delaware Reincorporation
REALITIES OF THE PROPOSED DELAWARE REINCORPORATION The proposed Delaware reincorporation is a brazen entrenchment maneuver that would strengthen the Board’s power at the expense of shareholder rights by: Precluding shareholders from filling director vacancies Raising the threshold for calling a Spec
Slide 50: Proposed Bylaws Would Make It Difficult to Call a Special Meeting
PROPOSED BYLAWS WOULD MAKE IT DIFFICULT FOR SHAREHOLDERS TO CALL A SPECIAL MEETING These unreasonably restrictive and overly burdensome requirements are clearly intended to deter and make it exceedingly difficult for a shareholder to request a special meeting The “Demand Record Date” request require
Slide 51: The Removal of Cumulative Voting Is a Ploy
THE REMOVAL OF CUMULATIVE VOTING IS A PLOY The Board is using cumulative voting as a scare tactic to misrepresent the Razin Group and our intentions • We believe that the proposal to remove cumulative voting was a “The bundling of a director election vote together blatant reactionary move to the Raz
Slide 52: Key Differences Between the Company's and Razin Group's Reincorporation
KEY DIFFERENCES BETWEEN THE COMPANY’S REINCORPORATION VS. THE RAZIN GROUP’S PROPOSED PRO-SHAREHOLDER REINCORPORATION PROVISION ENTRENCHED FOUR’S PROPOSALS RAZIN GROUP’S PROPOSALS 9 Committed to proposing an unfettered right Shareholder X Proposing to increase the percentage of shares required to cal
Slide 53: Our Solution: The Razin Group Slate
OUR SOLUTION: THE RAZIN GROUP SLATE
Slide 54: We Have Nominated the Right Slate for This Key Moment in Time
WE HAVE NOMINATED THE RIGHT SLATE FOR THIS KEY MOMENT IN TIME Our nominees collectively possess the experience, perspectives and knowledge that have been marginalized in the boardroom over the past six years Kenneth H. Fearn Sheldon Razin Lance E. Rosenzweig Ruby Sharma Mr. Fearn will help the Board
Slide 55: Biography for Kenneth H. Fearn
BIOGRAPHY FOR KENNETH H. FEARN Mr. Fearn has deep capital markets acumen, significant strategic planning experience and strong knowledge of public company governance. We believe he has the right background for helping the Board establish an accretive capital allocation framework and once again embra
Slide 56: Endorsements for Mr. Fearn
ENDORSEMENTS FOR MR. FEARN “I appreciate Ken’s operating, financial, and strategic expertise. He has shown a willingness to actively engage with our team, often asking the challenging questions in a direct but collegial manner which have been beneficial to the company. “ Monty J. Bennett, Chairman o
Slide 57: Biography for Sheldon Razin
BIOGRAPHY FOR SHELDON RAZIN Mr. Razin is a recognized leader in the healthcare technology space with years of service on NextGen Healthcare’s Board and extensive knowledge of the Company’s inner workings. We believe he has the best experience for helping the Board grow NextGen Healthcare and restori
Slide 58: Endorsements for Mr. Razin
ENDORSEMENTS FOR MR. RAZIN “ Every decision he makes is with a focus and commitment on building long term value for investors, customers and employees […] so if you want a board member that will help ensure decisions are made in the pursuit of long term and durable value, Shelly is an ideal candidat
Slide 59: Biography for Lance E. Rosenzweig
BIOGRAPHY FOR LANCE E. ROSENZWEIG Mr. Rosenzweig is a proven leader in the technology space with a strong track record of delivering outsized returns to shareholders. We believe his extensive success in the technology sector and deep knowledge of NextGen Healthcare as an 8-year director will help th
Slide 60: Endorsements for Mr. Rosenzweig
ENDORSEMENTS FOR MR. ROSENZWEIG “Lance has integrity, character, balance and humility. He works well with, and is respected by, all echelons in an organization. He is equally respected in the market, and never for a second forgets the purpose of a business is to create customers. “ Larry Bradford, f
Slide 61: Biography for Ruby Sharma
BIOGRAPHY FOR RUBY SHARMA Ms. Sharma is a certified financial expert with a vast background advising public companies, including those in the healthcare and technology sectors, on audit, finance and innovation strategies. We believe she is well-suited to serve on the Audit Committee to help improve
Slide 62: Endorsements for Ms. Sharma
ENDORSEMENTS FOR MS. SHARMA “ Ruby brings over 25 years’ experience in Audit & Accounting, Risk Management, Strategy & Corporate Governance to board service. […] She is an artful negotiator and communicator, comfortable with ambiguity and uncertainty. She is an asset in every “ boardroom. Barry Rabn
Slide 63: Our Slate's Value-Enhancing Ideas
OUR SLATE’S VALUE-ENHANCING IDEAS
Slide 64: What We Stand For
WHAT WE STAND FOR In addition to advocating for a holistic review of the Company's strategic priorities, we would raise the following suggestions in the boardroom: Creating a clear and Instituting a new executive Restructuring the sales team transparent capital allocation compensation plan that alig
Slide 65: Create a Clear and Transparent Capital Allocation Policy
CREATE A CLEAR AND TRANSPARENT CAPITAL ALLOCATION POLICY THAT IS DISCLOSED TO SHAREHOLDERS Given our slate of director candidates’ robust capital allocation expertise, we believe they can help the Board curb NextGen Healthcare’s SG&A burn and prioritize accretive investments • Our slate would advoca
Slide 66: Institute a New Executive Compensation Plan That Aligns Pay with Performance
INSTITUTE A NEW EXECUTIVE COMPENSATION PLAN THAT ALIGNS PAY WITH PERFORMANCE The Razin Group believes that executive compensation should reflect the performance of the Company • We believe that compensation should be oriented toward shareholder return, similar to how pay was configured prior to Mr.
Slide 67: Restructure the Sales Team and Establish Attractive Incentives
RESTRUCTURE THE SALES TEAM AND ESTABLISH ATTRACTIVE INCENTIVES TO SPUR INCREASED ORGANIC GROWTH Our director candidates believe it is essential to address the dysfunction across various sales functions head-on, given client attrition has gone up nearly 10% over the past year • Profit and loss (“P&L”
Slide 68: Reduce Spend on Consultants, Non-Accretive Initiatives and Outsourceable Services
REDUCE SPEND ON CONSULTANTS, NON-ACCRETIVE INITIATIVES AND SERVICES THAT COULD BE OUTSOURCED Our director candidates would commit to stemming the culture of excessive spending that currently permeates NextGen Healthcare • We believe that the Board could dramatically improve profitability in a single
Slide 69: Develop a Robust Succession Plan for All Senior Leadership Positions
DEVELOP A ROBUST SUCCESSION PLAN FOR ALL SENIOR LEADERSHIP POSITIONS If elected to the Board, our slate of director candidates would help ensure the Company prioritizes developing succession plans for the C-suite and key leadership positions • It’s our view that robust succession plans should be dev
Slide 70: Vote the Blue Card
VOTE THE BLUE CARD